spacer
home > ebr > summer 2018 > gene therapy
PUBLICATIONS
European Biopharmaceutical Review

Gene Therapy

In 2014, following a quarter of a century roller coaster trajectory, Ledley et al published very optimistic conclusions after their examination of life cycles of gene therapy, stating “Gene therapy technologies are now achieving the level of maturity that innovation research and biotechnology experience suggest may be requisite for efficient product development” (1). Looking at the following, it seems that reality meets those odds:

• The first marketing authorisations granted in the Western countries (Strimvelis® for the rare immunodeficiency syndrome adenosine-deaminase-severe combined immunodeficiency (ADA-SCID), Imlygic® [HSV1-GMCSF] for melanoma, Kymriah® for acute leukocytic leukemia, Yescarta® for non-Hodgkin lymphoma, Luxturna® for Leber congenital amaurosis)
• The steady maturation of the field since the 1980s (>40,000 papers, nearly 20,000 patents, >2,500 clinical trials including >100 late stage Phase 2/3 or Phase 3 trials)
• Billions in capital investments and initial public offerings (IPOs) in gene therapy companies, the activity being now driven by large pharmaceutical companies (with a peak reached recently with the $8.7 billion acquisition of Avexis by Novartis)

Gene therapy is defined as the introduction of genetic material into patients with an intended curative, life-extending, or life-enhancing therapeutic benefit. The applications rely on a myriad of possibilities, including the transient or permanent genetic modification of the administered product or ex vivo-engineered tissue to produce proteins for internal, local, or systemic use, helping to replace or correct faulty genes (in the case of rare diseases), providing stimuli to regenerate tissues (in the case of brain or cardiac disorders), killing tissues, or enhancing defence mechanisms (in the case of cancer or infectious diseases).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Serge Braun PharmD, PhD, is Scientific Director of AFM-Téléthon, President of Genosafe (a CRO company dedicated to quality control of biotherapeutic products) and Director Neuromuscular diseases at Généthon. He has 10 years of experience in the neuromuscular diseases field in the academic sector and 10 years in the biotech sector as Vice President of Research of Transgene SA. Serge was also co-founder of Neurofit, a CRO specialised in preclinical testings, and Vice President of Alsace BioValley, the non-profit making organisation for the development of a major biotech cluster in Europe. He also serves as advisor for Venture Capital companies and bioclusters.
spacer
Dr Serge Braun
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT Acquires Biological Specialty Corporation, Adds Donor Centers and Increases Its Immune Cell Capacity

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has acquired Biological Specialty Corporation (BSC), a supplier of human blood products and components to the life sciences research community for more than 37 years. BSC is headquartered in Colmar, PA, with two additional FDA-registered donor centers in Allentown, PA and Reading, PA.
More info >>

White Papers

Key to Outsourcing Method Development and Validation A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation.
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement